The main goal is to achieve a precision medicine approach for multiple myeloma and other hematological cancers. Predictive biomarkers serve for different objectives like patient stratification in clinical development of a new drug or to help clinician in the choose of therapeutic treatment by predicting how a patient will react to a treatment.
In order to achieve this, we have developed innovative biomathematical algorithms (4 patents) to develop gene expression signatures (biomarkers) that is indicative for the prediction of cancer cells sensitivity or resistance to a given drug. The interest of the identified biomarkers to predict MM cell sensitivity or resistance to the different treatments have been validated using primary myeloma cells of patients cocultured with their bone marrow microenvironment as previously described.
To enhance our capacity to develop signature of prediction of tumor cell responses at a therapeutic agent, we have characterized our myeloma cell lines collection and the model of differentiation of normal plasma cells at different molecular levels using Gene Expression Profiling, RNA-seq, Exome-seq, Whole genome seq, Chip-seq (6 different histone marks), Single Nucleotide Polymorphism analysis, DNA methylation analysis and miRNA-seq. We also derived drug resistant myeloma cell lines (dexamethasone, bortezomib, IMiDs, melphalan, HDACi, …) and have characterized them using the same strategy.